{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:42:24Z","timestamp":1740152544123,"version":"3.37.3"},"reference-count":35,"publisher":"Informa UK Limited","issue":"6","funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2018,6,3]]},"DOI":"10.1080\/17474086.2018.1475226","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:37:42Z","timestamp":1526431062000},"page":"503-511","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin\u2019s lymphoma progressing after brentuximab vedotin: an indirect treatment comparison"],"prefix":"10.1080","volume":"11","author":[{"given":"Sam","family":"Keeping","sequence":"first","affiliation":[{"name":"Evidence Synthesis and Decision Modeling, Precision Xtract, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Observational & Real World Evidence, Merck & Co, Inc, Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Chan","sequence":"additional","affiliation":[{"name":"Evidence Synthesis and Decision Modeling, Precision Xtract, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Mojebi","sequence":"additional","affiliation":[{"name":"Evidence Synthesis and Decision Modeling, Precision Xtract, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon Allen","family":"Ferrante","sequence":"additional","affiliation":[{"name":"Center for Observational & Real World Evidence, Merck & Co, Inc, Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Balakumaran","sequence":"additional","affiliation":[{"name":"Center for Observational & Real World Evidence, Merck & Co, Inc, Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,5,23]]},"reference":[{"volume-title":"DeVita, Hellman, and Rosenberg\u2019s cancer: principles & practice of oncology","year":"2011","author":"DeVita VT","key":"CIT0001"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60035-X"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.086"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2151"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.3239"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100340"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0910"},{"volume-title":"Cancer survival among adults: U.S. SEER Program, 1988-2001, patient and tumor characteristics","year":"2007","author":"Clarke C","key":"CIT0009"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.0910"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-288373"},{"key":"CIT0013","doi-asserted-by":"crossref","unstructured":"Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology [Practice Guideline]. J Natl Compr Canc Netw. 2017 May;15:608\u2013638.","DOI":"10.6004\/jnccn.2017.0064"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2013.02.002"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07727.x"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.798868"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12499"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0077-7"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu181"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw169"},{"issue":"9","key":"CIT0023","first-page":"5781","author":"Xu P","year":"2016","journal-title":"Onco Targets Ther"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0363-1"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.023"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"volume-title":"Food and Drug Administration","key":"CIT0027"},{"key":"CIT0028","unstructured":"European Medicines Agency. Keytruda (pembrolizumab) [cited 2017 Nov 1]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003820\/human_med_001886.jsp&mid=WC0b01ac058001d124"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-24"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.101"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X124558472"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00347.x"},{"key":"CIT0035","unstructured":"Phillippo D, Ades T, Dias S, et al. NICE DSU Technical Support Document 18. Vol. 18. NICE Decision Support Unit; 2016. (Methods for population-adjusted indirect comparisons in submissions to NICE)."}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2018.1475226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T19:05:17Z","timestamp":1661281517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2018.1475226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,23]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,3]]}},"alternative-id":["10.1080\/17474086.2018.1475226"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2018.1475226","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"type":"print","value":"1747-4086"},{"type":"electronic","value":"1747-4094"}],"subject":[],"published":{"date-parts":[[2018,5,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}